Abstract:Background: Advanced gastric cancer is a common malignancy that is often diagnosed at an advanced stage and is still at risk of recurrence after radical surgical treatment. Chemoradiotherapy, as one of the important treatment methods for gastric cancer, is of great significance for improving the survival rate of patients. However, the tumor recurrence and survival prognosis of gastric cancer patients after radiotherapy and chemotherapy are still uncertain. Aim: To analyze the tumor recurrence after radical radiotherapy and chemotherapy for advanced gastric cancer and provide more in-depth guidance for clinicians. Methods: A retrospective analysis was performed on 171 patients with gastric cancer who received postoperative adjuvant radiotherapy and chemotherapy in our hospital from 2021 to 2023. The Kaplan-Meier method was used to calculate the recurrence rate and survival rate; the log-rank method was used to analyze the single-factor prognosis; and the Cox model was used to analyze the prognosis associated with multiple factors. Results: The median follow-up time of the whole group was 63 months, and the follow-up rate was 93.6%. Stage II and III patients accounted for 31.0% and 66.7%, respectively. The incidences of Grade 3 and above acute gastrointestinal reactions and hematological adverse reactions were 8.8% and 9.9%, respectively. A total of 166 patients completed the entire chemoradiotherapy regimen, during which no adverse reaction-related deaths occurred. In terms of the recurrence pattern, 17 patients had local recurrence, 29 patients had distant metastasis, and 12 patients had peritoneal implantation metastasis. The 1-year, 3-year, and 5-year overall survival (OS) rates were 83.7%, 66.3%, and 60.0%, respectively. The 1-year, 3-year, and 5-year disease-free survival rates were 75.5%, 62.7%, and 56.5%, respectively. Multivariate analysis revealed that T stage, peripheral nerve invasion, and the lymph node metastasis rate (LNR) were independent prognostic factors for OS. Conclusion: Postoperative intensity-modulated radiotherapy combined with chemotherapy for gastric cancer treatment is well tolerated and has acceptable adverse effects, which is beneficial for local tumor control and can improve the long-term survival of patients. The LNR was an independent prognostic factor for OS. For patients with a high risk of local recurrence, postoperative adjuvant chemoradiation should be considered.

Survival Outcomes and Patterns of Failure after D2 Dissection and Adjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: a Retrospective Study.

Complete Mesogastric Excision for Locally Advanced Gastric Cancer: Short-Term Outcomes of a Randomized Clinical Trial

Identification of Patients with Locally Advanced Gastric Cancer Who May Benefit from Adjuvant Chemoradiotherapy after D2 Dissection: A Propensity Score Matching Analysis

Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy.

Benefit from Adjuvant Chemoradiation to Resected Stage Iiic Gastric Cancer Patients with D2 Lymph Node Dissection

Identification of Patients with Lymph Node Metastasis from Gastric Cancer Who May Benefit from Adjuvant Chemoradiotherapy after D2 Dissection-Do N3 Patients Benefit from Additional Radiation?

Analysis of recurrence for locally advanced gastric or gastroesophageal cancer patients after receiving curative gastrectomy ( ＞ D1 ) and its indication for adjuvant chemoradiotherapy

D2-Resected Stage Iiic Gastric Cancer Patients Benefit from Adjuvant Chemoradiotherapy

The Recurrence Patterns and Post-Recurrence Survivals in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (escc) Treated with Preoperative Paclitaxel/Cisplatin-Based Chemoradiotherapy.

Lymph Node Burden As A Predictive Factor for Selective Chemoradiotherapy in Patients with Locally Advanced Gastric Cancer after A D2 Dissection: A Retrospective Study

Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis

Tumor recurrence and survival prognosis in patients with advanced gastric cancer after radical resection with radiotherapy and chemotherapy

Short-term Surgical and Long-Term Survival Outcomes after Laparoscopic Distal Gastrectomy with D2 Lymphadenectomy for Gastric Cancer

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection

Resected Gastric Cancer with D2 Dissection: Advances in Adjuvant Chemoradiotherapy and Radiotherapy Techniques

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

The Effectiveness of Gastrectomy with Chemoradiotherapy among Stage IV Gastric Adenocarcinoma: A Population-Based Analysis

[Meta-Analysis of Adjuvant Chemotherapy on Prognosis for Gastric Cancer Patients after D2 Dissection].

Disease-Specific Survival of AJCC 8th Stage II Gastric Cancer Patients After D2 Gastrectomy

Survival Analysis of Stage II Gastric Cancer Patients after D2 Gastrectomy: a Chinese People-Based Research

Postoperative Chemoradiotherapy Versus Postoperative Chemotherapy For Completely Resected Gastric Cancer With D2 Lymphadenectomy: A Meta-Analysis